Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia

Pediatrics

Volumn 99, Issue 6, 1997, Pages 838-845

  Finer, Neil M ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHEMOGLOBIN; NITRIC OXIDE; NITROGEN DIOXIDE; SURFACTANT;

ARTICLE; BLOOD OXYGENATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL DIAPHRAGM HERNIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; HYPOXIA; INFANT; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE;

ADMINISTRATION, INHALATION; DOUBLE-BLIND METHOD; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; GESTATIONAL AGE; HERNIA, DIAPHRAGMATIC; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; METHEMOGLOBIN; NITRIC OXIDE; PROSPECTIVE STUDIES; RESPIRATORY INSUFFICIENCY; RESPIRATORY THERAPY; SURVIVAL ANALYSIS; TRANSPORTATION OF PATIENTS; VENTILATOR WEANING;

EID: 0030995049     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.99.6.838     Document Type: Article

References (47)

1. Metkus AP, Esserman L, Sola A, Harrison MR, Adzick NS. Cost per anomaly: what does a diaphragmatic hernia cost? J Pediatr Surg. 1995; 30:226-230
2. Harrison MR, Adzick S, Estes JM, Howell LJ. A prospective study of the outcome for fetuses with diaphragmatic hernia. JAMA. 1994;271: 382-384
3. Irish MS, Karamanoukian HL, O'Toole SJ, Glick PL. You gotta have heart. J Pediatr. 1996;129:175-176
4. Schwartz SM, Vermilion RP, Hirschl RB. Evaluation of left ventricular mass in children with left-sided congenital diaphragmatic hernia. J Pediatr. 1994;125:447-451
5. Neonatal ECMO Registry of the Extracorporeal Life Support Organization (ELSO). Ann Arbor, MI: July 1995
6. Field J and the UK Collaborative ECMO Trial Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet. 1996;348:75-82
7. Economic costs of birth defects and cerebral palsy - United States, 1992. MMWR. 1995;44:694-699
8. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989; 65:1-21
9. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3:31-36
10. Archer SL, Rist K, Nelson DP, DeMaster EG, Cowan N, Weir EK. Comparison of the hemodynamic effects of nitric oxide and endothelium-dependent vasodilators in intact lungs. J Appl Physiol. 1990;68: 735-747
11. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-2018
12. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526
13. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265-9269
14. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside, and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res. 1979;5:211-224
15. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153:1251-1256
16. Ignarro LJ, Adams JB, Horwitz PM, Wood KS. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. J Biol Chem. 1986;261:4997-5002
17. Burke-Wolin T, Abate CJ, Wolin MS, Gurtner GH. Hydrogen peroxide-induced pulmonary vasodilation: role of guanosine 3′,5′-cyclic monophosphate. Am J Physiol. 1991;261:L393-L398
18. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev Physiol Biochem Pharmacol. 1989;113:42-88
19. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide - a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991;83:2038-2047
20. Fratacci MD, Frostell CG, Chen TY, Wain JC, Robinson DR, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator of heparinprotamine vasoconstriction in sheep. Anesthesiology. 1991;75:990-999
21. Roberts JD, Chen TY, Kawai N, Wain J, Dupuy P, Shimouchi A, Bloch K, Polaner D, Zapol WM. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res. 1993;72:246-254
22. Zayek M, Cleveland D, Morin FC. Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide. J Pediatr. 1993;122:743-750
23. Higenbottam T, Pepke-Zaba J, Scott J, Wollman P, Coutts C. Wallwork J. Inhaled "endothelium-derived relaxing factor" (EDRF) in primary hypertension (PPH). Am Rev Respir Dis. 1988;137:A107
24. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 1991;338:1173-1174
25. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405
26. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340: 818-819
27. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:819-920
28. Kinsella JP, Neish SR, Dunbar I. Shaffer E, Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr. 1993; 123:103-108
29. Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr. 1994;124:302-308
30. Karamanoukian H, Glick P, Zayek M, et al. Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios. Pediatrics. 1994;94:715
31. Shah N, Jacob T, Exler R, Morrow S, et al. Inhaled nitric oxide in congenital diaphragmatic hernia. J Pediatr Surg. 1994;29:1010-1015
32. Frostell CG, Lonnqvist PA, Sonesson SE, et al. Near fatal pulmonary hypertension after surgical repair of congenital diaphragmatic hernia. Anesthesia. 1993;48:679-683
33. Kinsella JP, Neish SR, Dunbar I, Shatter E, Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr. 1993; 123:103-108
34. Henneberg SW, Jepsen S, Andersen PK, Pedersen SA. Inhalation of nitric oxide as a treatment of pulmonary hypertension in congenital diaphragmatic hernia. J Pediatr Surg. 1995;30:853-855
35. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597-604
36. Van Meurs KP, Sokol GM, Wright LL, Rivera O, Thom WJ. Minimizing nitrogen dioxide exposure during inhaled nitric oxide therapy. Pediatr Res. 1996;39:353A. Abstract
37. Sokol GM, Van Meurs KP, Thorn WJ, Rivera O, Wright LL, Sams RL. Nitrogen dioxide kinetics in a neonatal continuous flow ventilatory circuit. Pediatr Res. 1996;39:350A. Abstract
38. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 gm. J Pediatr. 1978;92:529-534
39. Karamanoukian HL, Glick PL, Wilcox DT, Rossman JE, Azizkhan RG. Pathophysiology of congenital diaphragmatic hernia X: localization of nitric oxide synthase in the intima of pulmonary artery trunks of lambs with surgically created congenital diaphragmatic hernia. J Pediatr Surg. 1995;30:5-9
40. North AJ, Moya FR, Mysore MR, et al. Pulmonary endothelial nitric oxide synthase gene expression is decreased in a rat model of congenital diaphragmatic hernia. Am J Respir Cell Mol Biol. 1995;13:676-682
41. Karamanoukian HL, Glick PL, Wilcox DT, Rossman JE, Holm BA, Morin FC. Pathophysiology of congenital diaphragmatic hernia VIII: inhaled nitric oxide requires exogenous surfactant therapy in the lamb model of congenital diaphragmatic hernia. J Pediatr Surg. 1995;30:1-4
42. O'Toole SJ, Karamanoukian HL, Sharma A, Morin FC, Holm BA, Azizkhan RG, Glick PL. Surfactant rescue in the fetal lamb model of congenital diaphragmatic hernia. J Pediatr Surg. 1996;31:1105-1109
43. Lotze A, Knight GR, Anderson KD, Hull WM, et al. Surfactant (Beractant) therapy for infants with congenital diaphragmatic hernia on ECMO. Evidence of persistent surfactant deficiency. J Pediatr Surg. 1994;29:407-412
44. Nio M, Haase G, Kennaugh J, Bui K, Atkinson JB. A prospective randomized trial of delayed vs immediate repair of congenital diaphragmatic hernia. J Pediatr Surg. 1994;29:618-621
45. Bos AP, Tibboel D, Koot VCM, Hazebroek FWJ, Molenaar JC. Persistent pulmonary hypertension in high-risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy. J Pediatr Surg. 1993;28: 1463-1465
46. Detsky AS, Sackett DL. When was a "negative" clinical trial big enough? Arch Intern Med. 1985;145:709-712
47. Wilcox DT, Glick PH, Karamanoukian HL, Leach C, Morin FC, Fuhrman BP. Perfluorocarbon-associated gas exchange improves pulmonary mechanics, oxygenation, ventilation, and allows nitric oxide delivery in the hypoplastic lung congenital diaphragmatic hernia lamb model. Crit Care Med. 1995;23:1858-1863